Please try another search
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
Christopher J. Kirk | 52 | 2015 | Co-Founder, CEO & Director |
Franklin M. Berger | 75 | 2016 | Independent Director |
Michael Glen Kauffman | 61 | 2016 | Independent Director |
John Franklin Fowler | 52 | 2015 | Co-Founder & Director |
Micki Klearman | 69 | 2021 | Independent Director |
Graham K. Cooper | 54 | 2017 | Independent Chairman |
Elizabeth Ijeoma Onyemelukwe Garner | 56 | 2019 | Independent Director |
Courtney Wallace | 40 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review